Extrapolating to gastric cancer, where resistance to platinum and fluoropyrimidine-based regimens is a major clinical challenge, Axl inhibition may sensitize tumor cells to cytotoxic agents by disrupting the protective signaling networks [45]. Here, AXL is linked to gastric cancer.